ACE2 and infection: Given that recombinant ACE-2 mitigates against experimental pneumocyte injury, and since SARS-CoV-2 spike protein can downregulate ACE-2[20], it has been considered that SARS-CoV-2 derived spike protein without actual infection might trigger endothelial cell dysregulation and immune activation[21].